RT Journal Article
SR Electronic
T1 Informing Variant Assessment using Structured Evidence from Prior Classifications (PS1, PM5, and PVS1 Sequence Variant Interpretation Criteria)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.16.22275073
DO 10.1101/2022.05.16.22275073
A1 Bhat, Vineel
A1 Adzhubei, Ivan A.
A1 Fife, James D.
A1 Lebo, Matthew
A1 Cassa, Christopher A.
YR 2022
UL http://medrxiv.org/content/early/2022/10/12/2022.05.16.22275073.abstract
AB Purpose To explore whether evidence of pathogenicity from prior variant classifications in ClinVar could be used to inform variant interpretation using the ACMG/AMP clinical guidelines.Methods We identify distinct SNVs which are either similar in location or in functional consequence to pathogenic variants in ClinVar, and analyze evidence in support of pathogenicity using three interpretation criteria.Results Thousands of variants, including many in clinically actionable disease genes (ACMG SFv3.0), have evidence of pathogenicity from existing variant classifications, accounting for 2.5% of non-synonymous SNVs within ClinVar. Notably, there are many variants with uncertain or conflicting classifications which cause the same amino acid substitution as other pathogenic variants (PS1, N=323), variants which are predicted to cause different amino acid substitutions in the same codon as pathogenic variants (PM5, N=7,692), and LOF variants which are present in genes where many LOF variants are classified as pathogenic (PVS1, N=3,635). The majority of these variants have similar computational predictions of pathogenicity and splicing impact as their associated pathogenic variants.Conclusion Broadly, over 1.4 million SNVs exome-wide could make use of information from previously classified pathogenic variants. We have developed a pipeline to identify variants meeting these criteria, which may inform interpretation efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support was provided by NIH grant R01HG010372 (V.B., I.A.A., J.D.F., M.L., C.A.C.) from the National Human Genome Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA pipeline which can be used to analyze variants from ClinVar and dbNSFP, as well as relevant input files, are provided online (https://github.com/cassalab/tocayo). Pre-computed lists of variants within ClinVar and exome-wide which meet PS1, PM5, and PVS1 criteria can be found here (https://doi.org/10.6084/m9.figshare.c.5914178.v1). https://github.com/cassalab/tocayo https://doi.org/10.6084/m9.figshare.c.5914178.v1